Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zonisamide versus carbamazepine monotherapy in newly diagnosed partial epilepsy
ACTRN12607000142437Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of zonisamide in epilepsy (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Proportion of subjects remaining seizure free for at least a 26 week period. Started Apr 2007; status: completed.
02
Drugs
zonisamide
03
Conditions
epilepsy
Beyond the preview
Go deeper on ACTRN12607000142437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000142437.